Leuven算法指导下胰岛素滴定实现正常空腹范围内 Tight 血糖控制对成人危重症患者的影响:TGC-fast随机对照试验
TGC-fast是一项由研究者发起的多中心随机对照试验,纳入无法进食、需动脉及中心静脉置管且无治疗限制的成人危重症患者,随机接受Tight血糖控制(80-110 mg/dl)或宽松血糖控制(仅当高血糖>215 mg/dl时启动胰岛素,目标180-215 mg/dl)。研究拟纳入9230例患者,以ICU依赖时间差异1天为主要终点、医院死亡率增加1.5%为安全性终点,旨在明确未接受早期肠外营养的成人危重症患者的最佳血糖控制策略。
要点
- Tight组目标血糖80-110 mg/dl,宽松组仅当血糖>215 mg/dl时启动胰岛素并目标180-215 mg/dl。
- Tight组采用经验证的LOGIC-Insulin软件指导,宽松组使用软件提醒以提高方案依从性。
- 研究拟纳入9230例,主要终点为ICU依赖时间差异1天,安全性终点为医院死亡率增加1.5%。
核心结论
- 危重症患者理想血糖目标仍存争议,该试验将为未接受早期肠外营养的成人危重症患者提供最佳血糖控制策略信息。
研究设计与样本
- TGC-fast为研究者发起的多中心随机对照试验,纳入无法进食、需动脉及中心静脉置管且无治疗限制的成人危重症患者,入ICU时随机分组。
- 干预持续至ICU出院、患者能进食或不再需要中心静脉置管,以先发生者为准。
- 研究拟纳入9230例患者,以至少80%把握度和5%α错误率检测ICU依赖时间差异1天(主要终点)及医院死亡率增加1.5%(安全性终点)。
关键数值与推荐
- Tight血糖控制目标为80-110 mg/dl,宽松血糖控制仅在血糖>215 mg/dl时启动胰岛素并目标180-215 mg/dl。
- 血糖测定采用动脉血气分析仪,必要时胰岛素仅经中心静脉持续给药;动脉置管不再需要时改用毛细血管血测定。
- Tight组由经验证的LOGIC-Insulin软件指导,宽松组使用软件提醒以最大化方案依从性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It remains controversial whether critical illness-related hyperglycemia should be treated or not, since randomized controlled trials (RCTs) have shown context-dependent outcome effects. Whereas pioneer RCTs found improved outcome by normalizing blood glucose in patients receiving early parenteral nutrition (PN), a multicenter RCT revealed increased mortality in patients not receiving early PN. Although withholding early PN has become the feeding standard, the multicenter RCT showing harm by tight glucose control in this context has been criticized for its potentially unreliable glucose control protocol. We hypothesize that tight glucose control is effective and safe using a validated protocol in adult critically ill patients not receiving early PN. METHODS: The TGC-fast study is an investigator-initiated, multicenter RCT. Patients unable to eat, with need for arterial and central venous line and without therapy restriction, are randomized upon ICU admission to tight (80-110 mg/dl) or liberal glucose control (only initiating insulin when hyperglycemia >215 mg/dl, and then targeting 180-215 mg/dl). Glucose measurements are performed on arterial blood by a blood gas analyzer, and if needed, insulin is only administered continuously through a central venous line. If the arterial line is no longer needed, glucose is measured on capillary blood. In the intervention group, tight control is guided by the validated LOGIC-Insulin software. In the control arm, a software alert is used to maximize protocol compliance. The intervention is continued until ICU discharge, until the patient is able to eat or no longer in need of a central venous line, whatever comes first. The study is powered to detect, with at least 80% power and a 5% alpha error rate, a 1-day difference in ICU dependency (primary endpoint), and a 1.5% increase in hospital mortality (safety endpoint), for which 9230 patients need to be included. Secondary endpoints include acute and long-term morbidity and mortality, and healthcare costs. Biological samples are collected to study potential mechanisms of organ protection. DISCUSSION: The ideal glucose target for critically ill patients remains debated. The trial will inform physicians on the optimal glucose control strategy in adult critically ill patients not receiving early PN. TRIAL REGISTRATION: ClinicalTrials.gov NCT03665207. Registered on 11 September 2018.
引用
- Gunst J, Mebis L, Wouters PJ, et al. Impact of tight blood glucose control within normal fasting ranges with insulin titration prescribed by the Leuven algorithm in adult critically ill patients: the TGC-fast randomized controlled trial. Trials. 2022. PMID: 36123593. doi:10.1186/s13063-022-06709-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。